

Respondents	No. of respondents	No. of responses/respondents	Avg. burden/response (in hrs.)	Total burden (in hrs.)
Initial Contact of Potential Candidates	1,600	1	0.16	267
Scheduling Interview	400	1	0.08	33
Telephone Interview	400	1	2	800
Total				1,108

5. State-Based Evaluation of Trends and Risk Factors in Morbidity and Mortality from Sickle Cell Disease after Newborn Screening—New—Children with sickle cell disease are at increased risk for mortality and morbidity, especially in the first three years of life. The need for early diagnosis and preventive medical intervention is the rationale for newborn hemoglobinopathy screening programs, now operating in more than 40 states. Although clinical trials have clearly

demonstrated the efficacy of early medical intervention, more information is needed regarding the actual utilization of available therapies and preventive measures in large populations, health statuses of children identified by newborn screening programs, and risk factors for adverse health outcomes. Potential risk factors include extent of medical care follow-up, location of treatment, the use of penicillin prophylaxis, immunization patterns, as well as parental social,

demographic and educational factors. In FY 1995, CDC awarded \$150,000 to three state health departments to assist in their efforts to ascertain health status and risk factors for young children with sickle cell disease. States will be using these funds to obtain information about individual children through structured questionnaires directed toward their parents and physicians. There are no costs to the respondents.

Respondents	No. of respondents	No. of responses/respondent	Avg. burden/response (in hrs.)	Total burden (in hrs.)
Parents	3,000	1	1.5	4.5
Physicians	4,500	1	1	4.5
Total				9

Dated: October 26, 1995.
Joseph R. Carter,
Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).
[FR Doc. 95-27056 Filed 10-31-95; 8:45 am]
BILLING CODE 4163-18-P

National Institute for Occupational Safety and Health; Meeting

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Breast Cancer Incidence Among Occupational Cohorts Exposed to Ethylene Oxide and Polychlorinated Biphenyls.

Time and Date: 9 a.m.-3:30 p.m.; December 13, 1995.

Place: Hubert Humphrey Building, Room 800, 200 Independence Avenue, SW., Washington, DC 20201.

Status: Open to the public, limited only by the space available. The room accommodates approximately 50 people.

Purpose: The purpose of this meeting is to obtain expert advice regarding technical and scientific aspects of the study "Breast Cancer Incidence Among Occupational Cohorts Exposed to Ethylene Oxide and Polychlorinated Biphenyls" being conducted at NIOSH. Participants on the Science

Advisory Panel will review the study protocol and provide advice on the conduct of the study.

Viewpoints and suggestions from industry, labor, academia, other government agencies and the public are invited.

Contact Person for Additional Information: Teresa Schnorr, Ph.D., NIOSH, CDC, Mailstop R-13, 4676 Columbia Parkway, Cincinnati, Ohio 45226, telephone 513/841-4587.

Dated: October 25, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-27030 Filed 10-31-95; 8:45 am]

BILLING CODE 4163-19-M

Public Health Service

Notice Regarding Section 602 of the Veterans Health Care Act of 1992 Contracted Pharmacy Services

AGENCY: Public Health Service, HHS.

ACTION: Notice.

SUMMARY: Section 602 of Public Law 102-585, the "Veterans Health Care Act of 1992" (the "Act"), enacted section 340B of the Public Health Service Act ("PHS Act"), "Limitation on Prices of Drugs Purchased by Covered Entities."

Section 340B provides that a manufacturer who sells covered outpatient drugs to eligible (covered) entities must sign a pharmaceutical pricing agreement with the Secretary of Health and Human Services (HHS) in which the manufacturer agrees to charge a price for covered outpatient drugs that will not exceed an amount determined under a statutory formula.

The purpose of this notice is to inform interested parties of the following proposed guidelines regarding contracted pharmacy services. Public comment is invited.

DATES: The public is invited to submit comments on the proposed guidelines by December 1, 1995. After consideration of the comments submitted, the Secretary will issue the final guidelines.

FOR FURTHER INFORMATION CONTACT: Marsha Alvarez, R. Ph., Director, Drug Pricing Program, Bureau of Primary Health Care, 4350 East-West Highway, Bethesda, MD 20814, Phone (301) 594-4353, FAX (301) 594-4982.

SUPPLEMENTARY INFORMATION: The Health Resources and Services Administration, Bureau of Primary Health Care, acting through the Office of Drug Pricing, has developed contracted pharmacy service guidelines to facilitate